Literature DB >> 16795064

Current status of lymph node-positive prostate cancer: Incidence and predictors of outcome.

Gregory P Swanson1, Ian M Thompson, Joseph Basler.   

Abstract

In early surgical series, the incidence of positive lymph nodes in patients with prostate cancer was approximately 40%. In the modern era of screening and improved patient selection, the incidence is now <10%, although most series excluded patients with higher risk disease. The risk of having positive lymph nodes is influenced by disease stage, prostate-specific antigen level, and tumor grade and by the aggressiveness of lymph node dissection. Many of the same factors predict the outcome of these patients. Although the percentage of patients with positive lymph nodes has declined, there remain significant numbers of patients with lymph node-positive prostate cancer, and it remains a therapeutic dilemma. Copyright 2006 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16795064     DOI: 10.1002/cncr.22034

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  18 in total

Review 1.  Reducing morbidity of pelvic and retroperitoneal lymphadenectomy.

Authors:  Mark W Ball; Michael A Gorin; Mohamad E Allaf
Journal:  Curr Urol Rep       Date:  2013-10       Impact factor: 3.092

2.  Celiac and perigastric lymph node metastasis of prostate cancer diagnosed with endoscopic ultrasound-guided fine-needle aspiration.

Authors:  T Attila; R Ricketts-Loriaux; D A Sauer; D O Faigel
Journal:  Can J Gastroenterol       Date:  2009-07       Impact factor: 3.522

3.  Integrating chemohormonal therapy and surgery in known or suspected lymph node metastatic prostate cancer.

Authors:  A J Zurita; L L Pisters; X Wang; P Troncoso; P Dieringer; J F Ward; J W Davis; C A Pettaway; C J Logothetis; L C Pagliaro
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-05-26       Impact factor: 5.554

4.  Identification of a clinically relevant androgen-dependent gene signature in prostate cancer.

Authors:  Hannelore V Heemers; Lucy J Schmidt; Zhifu Sun; Kevin M Regan; S Keith Anderson; Kelly Duncan; Dan Wang; Song Liu; Karla V Ballman; Donald J Tindall
Journal:  Cancer Res       Date:  2011-02-15       Impact factor: 12.701

Review 5.  Advances in Prostate Cancer Magnetic Resonance Imaging and Positron Emission Tomography-Computed Tomography for Staging and Radiotherapy Treatment Planning.

Authors:  Drew Moghanaki; Baris Turkbey; Neha Vapiwala; Behfar Ehdaie; Steven J Frank; Patrick W McLaughlin; Mukesh Harisinghani
Journal:  Semin Radiat Oncol       Date:  2016-08-31       Impact factor: 5.934

Review 6.  Management of prostate cancer patients with lymph node involvement: a rapidly evolving paradigm.

Authors:  Gilles Créhange; Chien Peter Chen; Charles C Hsu; Norbert Kased; Fergus V Coakley; John Kurhanewicz; Mack Roach
Journal:  Cancer Treat Rev       Date:  2012-06-15       Impact factor: 12.111

7.  Clinical significance of pelvic lymph node status in prostate cancer: review of 1690 cases.

Authors:  Livia Maccio; Valeria Barresi; Federica Domati; Eugenio Martorana; Anna Maria Cesinaro; Mario Migaldi; Francesco Iachetta; Antonio Ieni; Luca Reggiani Bonetti
Journal:  Intern Emerg Med       Date:  2016-02-13       Impact factor: 3.397

8.  [Imaging diagnostics of advanced prostate cancer].

Authors:  A Kretschmer; M Seitz; A Graser; C G Stief; D Tilki
Journal:  Urologe A       Date:  2013-04       Impact factor: 0.639

9.  Role of androgen deprivation therapy for node-positive prostate cancer.

Authors:  Yu-Ning Wong; Stephen Freedland; Brian Egleston; Gary Hudes; J Sanford Schwartz; Katrina Armstrong
Journal:  J Clin Oncol       Date:  2008-12-01       Impact factor: 44.544

10.  Challenges in clinical prostate cancer: role of imaging.

Authors:  Gary J Kelloff; Peter Choyke; Donald S Coffey
Journal:  AJR Am J Roentgenol       Date:  2009-06       Impact factor: 3.959

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.